By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD290 ‒ Liquid biopsies for early cancer detection, the role of epigenetics in aging, and the more
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
From DNA Sequencing to Liquid Biopsies and Reversing Epigenetic Aging
- Aravanis traces how sequencing fell from a roughly billion-dollar human genome project to a couple hundred dollars today, thanks to Illumina's miniaturized, massively parallel next-generation sequencing.
- Cell-free DNA shed by dying cells, including tumor cells, became the basis for liquid biopsies, and incidental cancer findings in prenatal testing helped motivate a universal cancer screening test and the founding of GRAIL.
- Methylation of cell-free DNA beat mutations, chromosomal changes and other features as the best signal, giving under 1% false positives, about 40% positive predictive value in the Pathfinder study, and tissue-of-origin prediction.
- Aravanis and Attia discuss whether early detection will improve survival, noting the NHS trial of about 140,000 people uses reduction in stage four cancers as a surrogate endpoint.
- The conversation turns to epigenetics as a possible root layer of aging, with methylation atlases, Yamanaka factors and partial reprogramming as routes toward rejuvenating specific tissues within a decade.
IDEAS WORTH REMEMBERING
5 ideasMiniaturization drove sequencing costs far below Moore's law.
Aravanis says sequencing the whole genome fell from hundreds of millions of dollars to a couple hundred dollars by shrinking reactions onto slides where billions of fragments are read in parallel using sequencing by synthesis.
Prenatal testing accidentally showed that cancer could be found in blood.
Abnormal chromosomal patterns in a few pregnant women's cell-free DNA turned out to reflect undiagnosed invasive cancers, showing high specificity in asymptomatic people even though it was not a screening test.
Specificity is the central requirement for broad cancer screening.
Earlier biomarkers like PSA were sensitive but had false positive rates of 5 to 10%, so GRAIL targeted roughly 1% or lower, which methylation analysis achieved.
Methylation was the dark-horse winner among cell-free DNA features.
It detected the most cancers, had the lowest false positive rate, and predicted tissue of origin, while adding other features did not help because they were not independent of the methylation signal.
A 40% positive predictive value is high for a screening test.
Aravanis contrasts it with mammography's roughly 4.5% and notes the test roughly doubled cancers found over standard screening in Pathfinder, mostly cancers with no screening test.
WORDS WORTH SAVING
5 quotesI call the, the epigenetics kind of the software of the genome, right? The, the genetic code is kind of the hardware, um, but how you use it, which gene you, genes you use when, what combination, that's really the epigenetics.
— Alex Aravanis
if, if you can't build it, you don't understand it, right? So simply understanding a description of something is not the same as you can build it up from scratch.
— Alex Aravanis
70% of people who die of cancer, they die from an unscreened cancer. So there's huge under-diagnosis, right?
— Alex Aravanis
if, if you wanna improve your prediction, y- you need an additional signal that carries information and is independent from your initial signal. If it's totally correlated, then it doesn't actually add anything, right?
— Alex Aravanis
the idea that we have this technology, and we're gonna allow huge numbers of cancers to just progress to late stage before treating, I, I, I don't think that's the right balance of, uh, potential benefit versus, um, uh, you know, kind of burden of evidence.
— Alex Aravanis
High quality AI-generated summary created from speaker-labeled transcript.
